Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial.

Huimin Lv, Yajing Feng, Tao Sun et al.|Journal of Clinical Oncology|2023

Cited by 3